MedTrace Logo

Study to Assess Safety and Tolerability of Multiple Doses of EO2002

NCT05636579 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-12-08

No results posted yet for this study

Summary

The goal of this clinical study is to assess the safety of multiple intracameral injections of EO2002 with and without topical Ripasudil.

Conditions

  • Corneal Edema
  • Corneal Endothelial Dystrophy
  • Endothelial Dysfunction
  • Fuchs Dystrophy
  • Fuchs' Endothelial Dystrophy
  • Bullous Keratopathy
  • Pseudophakic Bullous Keratopathy
  • Corneal Edema Pseudophakic

Interventions

BIOLOGICAL

EO2002

Intracameral injection of magnetic human corneal endothelial cells (EO2002)

DRUG

Ripasudil

Daily use of Ripasudil drops

Sponsors & Collaborators

  • Emmecell

    collaborator INDUSTRY

  • Asociación para Evitar la Ceguera en México

    lead OTHER

Principal Investigators

  • Valeria Sanchez Huerta, MD · Asociacion para Evitar la Ceguera

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-08
Primary Completion
2025-12-09
Completion
2025-12-09
FDA Drug
Yes

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05636579 on ClinicalTrials.gov